Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

89.44
Delayed Data
As of Feb 12
 +2.08 / +2.38%
Today’s Change
81.89
Today|||52-Week Range
123.37
-11.61%
Year-to-Date
Gilead Sciences Wants to Make Being a Shareholder Worth It
Feb 13 / MotleyFool.com
The Agony of High Returns
Feb 09 / MotleyFool.com
Novartis Filing for Neulasta Biosimilar Accepted in the EU
Feb 12 / Zacks.com
Why the Nasdaq is on the verge of a bear market
Feb 09 / CNNMoney.com
Why Intercept Pharmaceuticals Inc is Skyrocketing Today
Feb 12 / MotleyFool.com
Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck
Feb 09 / MotleyFool.com
Achillion Begins Study on First Complement Factor D Inhibitor
Feb 12 / Zacks.com
Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA
Feb 08 / Zacks.com
Shire Tops Q4 Earnings, Baxalta Buyout & Lifitegrast in Focus
Feb 12 / Zacks.com
Will Gilead Sciences, Inc. Continue to Dominate HIV Treatment?
Feb 08 / MotleyFool.com
Acorda Q4 Earnings Decline Y/Y, Ampyra & Pipeline in Focus
Feb 12 / Zacks.com
Morning Buzz: Yelp (YELP), Celgene (CELG), Gilead Sciences (GILD), Apple (AAPL), GoPr...
Feb 08 / Investing Channel
Market Rout Reveals True Bargains
Feb 12 / TheStreet.com
3 Health Care Stocks On The Rise
Feb 08 / TheStreet.com
These 7 Single-Digit P/E Stocks Could Collectively Deliver $600 Billion in Free Cash ...
Feb 12 / MotleyFool.com
Why Gilead Sciences (GILD) Stock May Advance Today
Feb 08 / TheStreet.com
Roche to Stop Study on Lung Cancer Drug Alecensa Early
Feb 11 / Zacks.com
Play Strong Defense With 3 Big Biotechs
Feb 07 / TheStreet.com
Genomic Health Q4 Loss Wider than Expected, Revenues Up
Feb 11 / Zacks.com
Is Gilead Sciences Finally Nearing a Bottom?
Feb 07 / MotleyFool.com
GW Pharmaceuticals Up on Narrower-than-Expected Q1 Loss
Feb 11 / Zacks.com
Grading Gilead Sciences' Performance in 2015
Feb 06 / MotleyFool.com
Friday Sector Leaders: Healthcare, Utilities
Feb 11 / TheOnlineInvestor.com
1 Company Gilead Sciences Should Consider Buying Right Now
Feb 06 / MotleyFool.com
Gilead Sciences Popular Amongst Latest 13F Filers
Feb 11 / HoldingsChannel.com
Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?
Feb 05 / MotleyFool.com
Gilead Sciences Becomes Oversold (GILD)
Feb 11 / DividendChannel.com
5 Stocks We're Buying Again
Feb 05 / MotleyFool.com
Buying Biotechs
Feb 11 / TheStreet.com
4 Can't-Miss Numbers From GlaxoSmithKline's Fourth-Quarter Results
Feb 04 / MotleyFool.com
Pfizer's Biosimilar of Remicade Recommended for Approval
Feb 10 / Zacks.com
Why Achillion Pharmaceuticals Shares Crashed 37% in January
Feb 04 / MotleyFool.com
Nasdaq Perilously Close to Bear Market: 5 Growth Stocks on Sale
Feb 10 / Zacks.com
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink
Feb 04 / Zacks.com
CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold
Feb 10 / Zacks.com
Why Did Biotech Fall Off a Cliff in January?
Feb 04 / MotleyFool.com
Gilead Sciences Inc.'s Outlook For 2016: What Investors Need to Know
Feb 10 / MotleyFool.com
Gilead's Stock is on Sale: Should You Buy?
Feb 03 / Zacks.com
Gilead (GILD) Stock Gains, Barclays Sees Upside Potential for Hep-C Drugs
Feb 10 / TheStreet.com
Forget Gilead Sciences: These Stocks Doubled Last Year
Feb 03 / MotleyFool.com
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Feb 10 / Zacks.com
Instant Analysis: Gilead Sciences Raises Its Dividend 10%
Feb 03 / MotleyFool.com
Stock Market News for February 10, 2016
Feb 10 / Zacks.com
Myriad Genetics Tops Q2 Earnings; myRisk Conversion Over
Feb 03 / Zacks.com
What to Expect from Gilead Sciences, Inc.'s New CEO
Feb 10 / MotleyFool.com
Qiagen Q4 Earnings Miss, Molecular Diagnostics Disappoints
Feb 03 / Zacks.com
3 Biotech Stocks to Buy in a Market Crash
Feb 09 / MotleyFool.com
International Growth Propels Gilead Sciences Inc.'s Solid Q4 Results
Feb 03 / MotleyFool.com
Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Feb 09 / Zacks.com
Alexion Misses on Earnings and Revenues in Q4, Gives View
Feb 03 / Zacks.com